Atlas Trials

Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients

Clinical trial NCT03528421 · UNKNOWN

Trial details

NCT number
NCT03528421
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Non Hodgkin Lymphoma
Start date
2018-05-22
Primary completion
2020-04-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.